Draflazine

Draflazine (R-75231) is a ENT1 inhibitor. Draflazine (R-75231) completely reverses the hypersensitivity in the complete Freund’s adjuvant (CFA) model of mechanical hyperalgesia and the carrageenan inflammation model of thermal and mechanical hyperalgesia[1].

Product Specifications

CAS Number

[120770-34-5]

Product Name Alternative

R-75231; R88021

UNSPSC

12352005

Target

Adenosine Receptor; Nucleoside Transporters

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/draflazine.html

Purity

99.06

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=C(Cl)C=C(N)C=C1Cl)CN2C(C(N)=O)CN(CCCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2

Molecular Formula

C30H33Cl2F2N5O2

Molecular Weight

604.52

References & Citations

[1]Maes SS, et al. Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs. J Pain Res. 2012;5:391-400.